A consortium formed by IVI RMA and GED Capital reached an agreement with Fresenius to acquire Eugin for $500 million, including earnings. The former will keep the business in the United States and Canada, the latter will retain the rest.
With this acquisition, IVI RMA solidifies itself as the world leader in assisted reproductive treatments. This is the company’s first major operation since Javier Sánchez Prieto took over as CEO, and Prieto said in a statement: “We are delighted to integrate Eugin’s operations in the USA and Canada into the IVI RMA group. Our spirit of care “Comprehensive and personalized treatment , will help us ensure we deliver a world-class experience and satisfying results to more patients.”
Eugin is one of the most relevant operators in the United States and Canada and includes the Boston IVF businesses in the United States, Trio in Canada and medical collaborations with Harvard Medical School, with total sales of approximately 150 million euros.
This acquisition of IVI RMA adds to the acquisition of Conceptions, Colorado’s leading independent operator, made several months ago. With both acquisitions, the group achieves one of its goals after KKR’s investment: to become one of the leading operators in the American market, as well as in most of the relevant markets in Europe. Following this operation, the American market became the largest and most relevant market for the group led by Sánchez Prieto, after doubling its sales compared to the previous year.
Since the arrival of KKR at the beginning of this year, IVI RMA has experienced rapid growth, and the recent addition of Javier Sánchez-Prieto as CEO has supported the company’s professionalization and consolidation as a world leader in reproductive treatments. helped. At the same time, IVI’s founder Antonio Pellicer continues to lead the strategy in the field of science and innovation that has always characterized the group.